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HEPARIN-INDUCED CARDIAC TAMPONADE AND
LIFE-THREATENING HYPERKALEMIA IN A PATIENT
WITH CHRONIC HEMODIALYSIS
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Heparin, a commonly used anticoagulant agent, is frequently used in patients undergoing hemodialysis.
As with most medications, heparin has a significant side effect profile. Two of its most important side
effects, major bleeding and hyperkalemia, may be devastating without immediate diagnosis and treatment.
Major bleeding such as gastrointestinal, genitourinary or intracranial bleeding is occasionally encountered
and rarely neglected. However, heparin-induced cardiac tamponade is rarely encountered and may be
easily overlooked. Another side effect, heparin-induced hyperkalemia, an unusual but well-described side
effect, is frequently forgotten until life-threatening arrhythmia has occurred. We report a case involving
a 40-year-old male patient with uremia, who had received heparin for 10 days for deep vein thrombosis
in the left lower extremity. Hemopericardium with cardiac tamponade and life-threatening hyperkalemia
were both noted in this patient.
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As with most medications, heparin has a variety of side
effects, including bleeding, thrombocytopenia [1,2], cumu-
lative dose-dependent osteoporosis, skin necrosis, alo-
pecia, hypersensitivity reactions, hypoaldosteronism [3]
and hyperkalemia [4–9]. The major complication of heparin
is bleeding. Factors that predispose a patient to bleeding
include advanced age, serious concurrent illness, heavy
consumption of alcohol, concomitant use of aspirin, and
renal failure [3]. Another side effect, heparin-induced
hyperkalemia, is an unusual but well-described side effect
[4–9]. Patients at risk for heparin-induced hyperkalemia
include those with diabetes mellitus (DM), renal insuf-
ficiency, metabolic acidosis, the elderly, and those receiving
concomitant drugs that can produce hyperkalemia [7,10,
11]. We report a patient with uremia, who had received
heparin for 10 days for deep vein thrombosis (DVT) in the
left lower extremity. As a result, hemopericardium with
cardiac tamponade and life-threatening hyperkalemia
developed in this patient.
CASE PRESENTATION
A 40-year-old male patient suffering from left thigh swelling
and redness for 2 weeks was admitted to the cardiovascular
ward at Kaohsiung Medical University. Tracing his medical
history, we found him to have end-stage renal disease with
regular hemodialysis (HD), DM with regular insulin control,
and hypertension with regular drug control. Due to the
symptoms in his left thigh, he was initially admitted to
St. Joseph’s Hospital in Kaohsiung, where a retrograde
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venography was performed and the patient was found to
have DVT in his left lower extremity. He was prescribed
heparin. As his symptoms did not subside after heparin use
for 2 days, he was transferred to our hospital for further
care. At our hospital, heparin treatment was continued,
keeping partial thromboplastin time (PTT) within 1.5 to 2
times normal. At admission, 12-lead electrocardiography
(ECG) showed normal tracing (Figure 1A), chest X-ray
(CXR) showed mild cardiomegaly (cardiothoracic ratio 57%)
(Figure 2A), and echocardiography showed only moder-
ate mitral regurgitation without pericardial effusion (Fig-
ure 3A). The patient’s laboratory data at admission are
summarized in the Table. On the seventh hospital day,
Tc-99m-labeled red blood cell subcutaneous radionuclide
venography was performed and revealed resolution of the
left thigh DVT. Heparin was discontinued on the eighth
hospital day. Dyspnea was noted on the ninth hospital day.
At that time, the patient’s breathing sounds indicated
bilateral lower lung inspiratory crackle, and CXR revealed
cardiomegaly with pulmonary congestion (Figure 2B). As
he was first suspected of having dyspnea caused by fluid
overload, emergency additional HD was performed. How-
ever, after emergency HD, dyspnea only partially im-
proved. On the 10th hospital day, dyspnea was aggravated
again and all-purpose O2 (60%, 10 L) was used. Arterial
blood gas showed: pH, 7.378; PCO2, 29.6 mmHg; PO2,
101.8 mmHg; HCO3, 17.1 mmol/L; SaO2, 97.5%. The patient
suddenly lost consciousness and went into cardiac arrest,
for which cardiopulmonary resuscitation (CPR) was initi-
ated. After 3 minutes of CPR and treatment with empiri-
cal intravenous epinephrine and calcium gluconate, the
ECG monitor showed ventricular fibrillation waves, and
the patient was administered direct-current (DC) shock
200 J. After DC shock, the ECG monitor showed wide-QRS
rhythm without P waves (Figure 1B). Hyperkalemia-induced
arrhythmia was suspected, so another dose of calcium
gluconate and standard potassium-lowering agents were
administered. The patient’s pulse gradually recovered, but
shock (blood pressure, 70/40 mmHg) was noted and the
inotropic agent, dopamine, was administered. His laboratory
data after this episode are listed in the Table. Twelve-lead
ECG showed first-degree atrioventricular node block and
higher T waves in leads V2–V6 (Figure 1C). We thoroughly
reviewed his CXR films and found that the CXR of the ninth
hospital day indicated a larger heart size (cardiothoracic
ratio, 66%) than previous films (Figure 2B). Immediate
bedside echocardiography was performed and the patient
was found to be experiencing severe pericardial effusion
with right ventricular (RV) early diastolic collapse (Figure
Figure 1. Electrocardiograms. (A) At admission, 12-lead electro-
cardiography (ECG) showed normal tracing. (B) After cardiopul-
monary resuscitation and direct-current shock, ECG showed wide-
QRS rhythm without P waves. (C) After resuscitation and treatment
with potassium-lowering agents, 12-lead ECG showed first-degree
atrioventricular block and higher T waves in leads V2–V6.
 A
B
C
3B). Emergency pericardiocentesis was performed and 800
mL dark-red pericardial effusion was drained. After pericar-
diocentesis, RV early diastolic collapse disappeared (Fig-
ure 3C) and blood pressure returned to 110/70 mmHg.
Because potassium was still high (8.7 mmol/L) after treat-
ment, a second emergency additional HD was given af-
ter pericardiocentesis. The patient gradually regained con-
sciousness and was weaned from the endotracheal tube
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DISCUSSION
Heparin, the most commonly used anticoagulant agent, is
frequently used in patients with acute coronary syndrome,
stroke, pulmonary embolism, DVT, and patients receiving
diagnostic or therapeutic procedures which may induce
thrombosis, such as coronary angiography, percutaneous
coronary intervention, and HD. Heparin has been reported
to have a variety of side effects, including bleeding, thrombo-
cytopenia, osteoporosis, skin necrosis, alopecia, hyper-
sensitivity reactions, hypoaldosteronism and hyperkalemia
[1–9]. Among the side effects, major bleeding and hyper-
kalemia may be the most devastating if not immediately
diagnosed and treated. Major bleeding, such as gastro-
intestinal bleeding, genitourinary or intracranial bleeding,
is occasionally encountered and rarely overlooked. How-
ever, heparin-induced massive pericardial effusion is rarely
encountered and can easily be overlooked without a detailed
examination, and diagnosis is not usually established until
cardiac tamponade develops. Another side effect, heparin-
induced hyperkalemia, is also unusual but well-described
in previous reports [4–9]. This side effect is frequently
Table. Laboratory data
Upon After cardiopulmonary
admission resuscitation
WBC (× 109/L) 13.72 10.27
Hemoglobin (g/L) 62 67
Platelets (× 109/L) 350 566
GOT/GPT (U/L) 19/21 1,124/751
Na/K/Cl (mmol/L) 128/4.8/89 136/9.2/94
PT (s) (patient/control) 12.9/11.4 –
PTT (s) (patient/control) 48.6/32.2 –
Bilirubin (T/D) (µmol/L) 12.0/5.1 20.5/6.0
CK/CK-MB (U/L) – 316/3.7
Troponin-I (µg/L) – 0.42
WBC = white blood cell; GOT = glutamate-oxaloacetate transaminase;
GPT = glutamate-pyruvate transaminase; PT = prothrombin time;
PTT = partial thromboplastin time; T = total; D = direct; CK = creatine
kinase; MB = isoenzymes from myocardial tissue.
Figure 2. Chest X-ray (CXR) films. (A) At admission, CXR showed mild cardiomegaly (cardiothoracic ratio, 57%). (B) On the ninth hospital day,
CXR revealed a larger heart size (cardiothoracic ratio, 66%) than previous films.
B A
after being intubated for 24 hours. Thereafter, serum
potassium level gradually decreased and pericardial effu-
sion did not accumulate again. He was discharged without
event 19 days after admission.
Component
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overlooked until life-threatening arrhythmia is noted [4]. In
our case, heparin was used for 10 days to treat left lower
extremity DVT. We discontinued it because repeated
venography revealed that his DVT had resolved. Two days
after discontinuation, however, the patient was found to
have developed hemopericardium with cardiac tam-
ponade and life-threatening hyperkalemia. Emergency
pericardiocentesis and HD were successfully performed
and he was discharged after 19 days of hospitalization.
Drug-induced hemopericardium with cardiac tamponade
has been reported to occur in patients using thrombolytic
agents or glycoprotein IIb-IIIa receptor antagonists [12–15].
Malouf et al, studying the role of anticoagulation in the
development of pericardial effusion and late tamponade after
Figure 3. Echocardiograms. (A) At admission, M-mode echocardiography
showed no pericardial effusion. (B) Before pericardiocentesis, M-mode
echocardiography showed right ventricular (RV) early diastolic collapse.
(C) Just after pericardiocentesis, repeated M-mode echocardiography
showed disappearance of RV early diastolic collapse.
 C
B
cardiac surgery, demonstrated that larger pericardial effusions
and cardiac tamponade were more likely to occur among
patients if they were excessively anticoagulated [16]. In our
case, although heparin was used for 10 days, PTT remained
within the therapeutic range and no excessive anticoagulation
was noted. However, this patient was uremic, and renal fail-
ure has been proven to predispose patients using heparin
to bleeding [3]. Although echocardiography at admission
revealed no pericardial effusion, hemorrhagic pericardial
effusion gradually developed in the patient after prolonged
heparin use. This pericardial effusion eventually became large
enough to cause cardiac tamponade, which was diagnosed by
repeated echocardiography. Emergency pericardiocentesis
was successfully performed and 800 mL of bloody pericar-
dial effusion was drained. After pericardiocentesis, echocar-
diographic signs of cardiac tamponade (RV early diastolic
collapse) disappeared and the patient experienced an imme-
diate elevation of blood pressure.
Hyperkalemia may result from a variety of factors, includ-
ing an increase in potassium intake, a decrease in potassi-
um excretion, or a shift of potassium from intracellular to ex-
tracellular fluid [17]. Many drugs, including potassium sup-
plements, angiotension-converting enzyme inhibitors, non-
steroidal anti-inflammatory drugs, and potassium-sparing
diuretics, may also cause hyperkalemia. Numerous case reports
have implicated heparin as a cause of hyperkalemia [4–9] and
several mechanisms may be responsible for heparin-induced
hyperkalemia [18]. Heparin appears to directly interfere with
the production of aldosterone, reduce the number and affinity
of angiotension II receptors, and induce a progressive atrophy
of the zona glomerulosa. Inhibition of aldosterone occurs
within 1 week after the initiation of heparin [11]. However,
clinically significant hyperkalemia rarely occurs and is often
transient because most patients are able to compensate through
other mechanisms that decrease serum potassium [19]. Patients
at risk for heparin-induced hyperkalemia are those unable to
compensate for decreased aldosterone concentrations by
regulating serum potassium through other pathways. These
include patients with DM, renal insufficiency, metabolic
acidosis, the elderly, and those receiving concomitant drugs
that can produce hyperkalemia [7,10,11]. Prolonged heparin
therapy has also been associated with a greater risk of
hyperkalemia [7]. When hyperkalemia does occur, it usually
becomes detectable between days 1 and 3 of heparin admin-
istration, peaks between days 3 and 5, continues for the
duration of heparin therapy, and returns to normal within
1 week after discontinuation of the drug [18,19]. In our case,
serum potassium level was 4.8 mmol/L at admission. During
his stay at the hospital, he did not receive a potassium-rich
A
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diet. The patient had uremia and was receiving regular HD.
Before he was found to have hyperkalemia, he was not only
receiving regular HD, but, as he was suspected of having
dyspnea caused by fluid overload, he had also received
additional emergency HD. Therefore, his diet and a decrease
in potassium excretion were not the likely causes of his
hyperkalemia. His hyperkalemia was caused by either over-
production or intercellular shift, or it was drug-induced.
No apparent source of potassium overproduction was noted
in our case, except massive bloody pericardial effusion. Al-
though we found a report of hyperkalemia associated with
massive cephalhematoma in a newborn infant [20], this
cause was unlikely because we found no evidence of hemoly-
sis (follow-up total/direct bilirubin level, 20.5/6.0 µmol/L).
Metabolic acidosis was noted in our patient. This acid-base
abnormality might result in a shift of potassium from intra-
cellular to extracellular fluid and cause hyperkalemia. How-
ever, this metabolic acidosis might play a minor role
in the development of hyperkalemia because the additional
emergency HD could excrete potassium shifted from intra-
cellular fluid. Our patient was a DM case with uremia,
which, as mentioned earlier, predisposed him to heparin-
induced hyperkalemia [7,10–11]. Consequently, pro-
longed use of heparin probably played a major role in
the development of hyperkalemia in our case.
The major treatment for heparin-induced hyperkalemia is
discontinuation of the drug. Potassium concentrations gen-
erally return to normal within 1 week after discontinuation of
heparin [11,18]. If discontinuation of heparin is not feasible,
fludrocortisone has been reported to be a reasonable therapy
for these patients [21]. In our case, discontinuation of heparin,
standard potassium-lowering agents and emergent additional
HD were successfully performed to reverse the complication
of hyperkalemia and hyperkalemia-induced life-threatening
arrhythmia.
In conclusion, our case demonstrates that prolonged
heparin use may simultaneously cause cardiac tamponade
and life-threatening hyperkalemia. These side effects are
frequently overlooked until patients develop serious
complications. Therefore, a series of serum potassium
concentration monitors and echocardiography follow-up
are necessary to avoid these lethal complications in patients
receiving heparin for prolonged periods.
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